Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-RGS2 siRNA
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intratumoral, Intrathecal, Intravitreal, Topical, Intradermal, Intranasal, Inhalation
01
Overview
anti-RGS2 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the Regulator of G protein signaling 2 (RGS2) gene. RGS2 is a critical modulator of G protein-coupled receptor (GPCR) signaling, specifically acting as a GTPase-activating protein (GAP) to terminate Gαq-mediated bronchoconstrictive signals. In research settings, such as studies on human airway smooth muscle (HASM) cells, anti-RGS2 siRNA is used to model the effects of RGS2 deficiency, which is associated with a hypercontractile phenotype and increased asthma exacerbation rates. By reducing RGS2 protein levels, the siRNA enhances intracellular calcium flux and contractile responses to agonists like histamine and methacholine, thereby validating the causal relationship between reduced RGS2 expression and airway hyperresponsiveness.
- Other names
- RGS2 siRNARGS-2 siRNARGS 2 siRNA
02
Targets
RGS2
Beyond the preview
Go deeper on anti-RGS2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-RGS2 siRNA.